X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Dishman Pharma with SUVEN LIFE - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DISHMAN PHARMA vs SUVEN LIFE - Comparison Results

DISHMAN PHARMA    Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DISHMAN PHARMA SUVEN LIFE DISHMAN PHARMA/
SUVEN LIFE
 
P/E (TTM) x 25.1 16.0 157.0% View Chart
P/BV x 3.3 3.8 88.2% View Chart
Dividend Yield % 0.7 0.5 144.0%  

Financials

 DISHMAN PHARMA   SUVEN LIFE
EQUITY SHARE DATA
    DISHMAN PHARMA
Mar-16
SUVEN LIFE
Mar-17
DISHMAN PHARMA/
SUVEN LIFE
5-Yr Chart
Click to enlarge
High Rs374229 163.9%   
Low Rs129151 85.3%   
Sales per share (Unadj.) Rs197.842.7 463.2%  
Earnings per share (Unadj.) Rs21.26.9 309.6%  
Cash flow per share (Unadj.) Rs34.78.5 407.0%  
Dividends per share (Unadj.) Rs2.001.00 200.0%  
Dividend yield (eoy) %0.80.5 150.8%  
Book value per share (Unadj.) Rs179.952.4 343.3%  
Shares outstanding (eoy) m80.69127.28 63.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.34.4 28.6%   
Avg P/E ratio x11.927.7 42.8%  
P/CF ratio (eoy) x7.222.2 32.6%  
Price / Book Value ratio x1.43.6 38.6%  
Dividend payout %9.414.6 64.6%   
Avg Mkt Cap Rs m20,30624,158 84.1%   
No. of employees `0000.81.0 81.6%   
Total wages/salary Rs m5,355522 1,026.4%   
Avg. sales/employee Rs Th19,252.75,349.7 359.9%   
Avg. wages/employee Rs Th6,459.5513.5 1,258.0%   
Avg. net profit/employee Rs Th2,064.1858.1 240.5%   
INCOME DATA
Net Sales Rs m15,9615,435 293.6%  
Other income Rs m265211 125.8%   
Total revenues Rs m16,2265,646 287.4%   
Gross profit Rs m4,1031,291 317.9%  
Depreciation Rs m1,091214 509.4%   
Interest Rs m94457 1,662.7%   
Profit before tax Rs m2,3341,231 189.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m10-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m624359 173.8%   
Profit after tax Rs m1,711872 196.3%  
Gross profit margin %25.723.7 108.3%  
Effective tax rate %26.729.2 91.7%   
Net profit margin %10.716.0 66.8%  
BALANCE SHEET DATA
Current assets Rs m11,0184,917 224.1%   
Current liabilities Rs m9,5171,186 802.4%   
Net working cap to sales %9.468.6 13.7%  
Current ratio x1.24.1 27.9%  
Inventory Days Days11062 177.8%  
Debtors Days Days3531 113.2%  
Net fixed assets Rs m16,3043,154 516.9%   
Share capital Rs m161127 126.8%   
"Free" reserves Rs m12,9076,543 197.3%   
Net worth Rs m14,5166,670 217.6%   
Long term debt Rs m4,189259 1,615.7%   
Total assets Rs m29,8058,157 365.4%  
Interest coverage x3.522.7 15.3%   
Debt to equity ratio x0.30 742.4%  
Sales to assets ratio x0.50.7 80.4%   
Return on assets %8.911.4 78.3%  
Return on equity %11.813.1 90.2%  
Return on capital %17.518.6 94.3%  
Exports to sales %24.80-   
Imports to sales %3.70-   
Exports (fob) Rs m3,956NA-   
Imports (cif) Rs m596NA-   
Fx inflow Rs m4,9524,996 99.1%   
Fx outflow Rs m697959 72.7%   
Net fx Rs m4,2554,037 105.4%   
CASH FLOW
From Operations Rs m2,7861,088 256.0%  
From Investments Rs m-1,529-3,107 49.2%  
From Financial Activity Rs m-941-300 313.5%  
Net Cashflow Rs m316-2,319 -13.6%  

Share Holding

Indian Promoters % 61.4 63.4 96.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 3.7 0.0 -  
FIIs % 12.7 0.0 -  
ADR/GDR % 0.0 0.0 -  
Free float % 22.1 36.5 60.5%  
Shareholders   46,261 37,287 124.1%  
Pledged promoter(s) holding % 35.8 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DISHMAN PHARMA With:   ALKEM LABORATORIES  PLETHICO PHARMA  VENUS REMEDIES  FRESENIUS KABI ONCO.  GLENMARK PHARMA  

Compare DISHMAN PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 219 Points Lower; Energy and Auto Stocks Witness Selling(Closing)

After witnessing volatile trades during the day, Indian share markets ended their session on a negative note. Losses were largely seen in the oil & gas sector, auto sector.

Related Views on News

Suven Lifesciences: Profits Decline due to Higher tax outgo in the quarter (Quarterly Results Update - Detailed)

Sep 22, 2017

Muted growth in CRAMS segment continues to impact topline.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

Alert: Pharma Stocks Are About to Shoot Up - And a Superb Stock for Trading(Profit Hunter)

Jun 13, 2018

The ailing pharma stocks are bouncing back to health. Read this to find out the best way to profit from them.

Will You Dump Your Client if You're Busy? Inox Wind's Auditor Just Did...(The 5 Minute Wrapup)

Jun 14, 2018

After Inox Wind, you may see more auditors resigning And the reasons can be as funny as they can get.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Should You Invest In Mirae Asset Healthcare Fund?(Outside View)

Jun 15, 2018

Mirae Asset Mutual Fund launches NFO - Mirae Asset Helathcare Fund.

This Behaviour is Injurious to Wealth Building(Sector Info)

Jun 13, 2018

Blindly following the herd can be the biggest wealth destroyer.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DISHMAN PHARMA SHARE PRICE


May 29, 2017 (Close)

TRACK DISHMAN PHARMA

  • Track your investment in DISHMAN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DISHMAN PHARMA

DISHMAN PHARMA 5-YR ANALYSIS

COMPARE DISHMAN PHARMA WITH

MARKET STATS